day 1 - Bsbb

More documents

Recommendations

Info

Discussion and Perspectives• This in vivo study focused on potentially confoundingsituations which therefore called for a multiparameterapproach.• First days:– At day 1, DCA can discriminate between 5 Gy TBI andequivalent PBI from 30% to 90% BM exposed.– Bio-markers: ANC, N/L ratio, CRP, citrulline.• Between 10 and 21 days:– TBI vs PBI discrimination possible using ANC, PLT, Hb,Flt-3 ligand (clinical re-evaluation of heterogeneouslyexposed individuals).• This model should be tested for a larger dose range of TBIand PBI. New markers such as circulating miRNA or organspecificindicators to be investigated.• A careful interpretation should be made (small size of thegroups).
AcknowledgmentsIRBA / CRSSA• Marco Valente• Nancy Grenier• Stéphane Baugé• Josiane Denis• Jean-François Mayol• Hervé Chaussard• Patrick Martigne• Michel DrouetCollaborations• Pr Michael Abend (IRBW):gene expression analysis• Dr George Sigal (Meso ScaleDiagnostics): multiplexedplatform for serum proteins
Page 1 and 2: A multiparameter approach to assest
Page 3 and 4: A study designed to account for acc
Page 5 and 6: Multiparameter approach (>50)• Cl
Page 7 and 8: Statistical analysis: PLS-DA• Sof
Page 9 and 10: Dicentric assay (day 1)1,42.5 Gy TB
Page 11 and 12: Hematology
Page 13 and 14: 140Platelet count (% of baseline)12
Page 15 and 16: Bone marrow assessment• Hematopoi
Page 17 and 18: CRP (mg/L)1201008060405 Gy TBI10 Gy
Page 19: What about other early bioindicator

day 1 - Bsbb

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?